down arrow

RPG LifeScience.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Drugs
  • ISIN: INE105J01010
  • NSEID: RPGLIFE
  • BSEID: 532983
INR
2,085.35
106.35 (5.37%)
BSENSE

Apr 11, 12:53 PM

BSE+NSE Vol: 7.9 k

Click here to access the older version
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2,012.452,099.35

52 Week

1,382.552,976.70
Valuation
Technical
Day's Volume

CASH

7.9 k (-34.78%) Volume

Shareholding (Dec 2024)

FII

1.30%

Held by 47 FIIs

DII

6.06%

Held by 5 DIIs

Promoter

72.95%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Dashboard
1

High Management Efficiency with a high ROE of 21.33%

 
2

Company has a low Debt to Equity ratio (avg) at 0 times

 
3

Poor long term growth as Net Sales has grown by an annual rate of 12.37% over the last 5 years

 
4

Positive results in Dec 24

5

Stock is technically in a Mildly Bearish range

6

With ROE of 22.9, it has a Fair valuation with a 8.6 Price to Book Value

7

Increasing Participation by Institutional Investors

stock-summaryMojo Parameters
Mojo Parameters
Loading Valuation Snapshot...
Stock DNA
stock-summary
Industry

Pharmaceuticals & Drugs

stock-summary
Market cap

INR 3,449 Cr (Small Cap)

stock-summary
P/E

38.00

stock-summary
Industry P/E

33

stock-summary
Dividend Yield

0.81%

stock-summary
Debt Equity

-0.33

stock-summary
Return on Equity

22.86%

stock-summary
Price to Book

8.63

Revenue and Profits (1 Year):
Net Sales:
173 Cr
(Quarterly Results - Dec 2024)
Net Profit:
35 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0.81%)
TimePeriod
Price Return
Dividend Return
Total Return
6 Months
-25.21%
0%
-25.21%
1 Year
37.36%
1.07%
38.43%
2 Years
181.54%
3.59%
185.13%
3 Years
251.28%
8.20%
259.48%
4 Years
417.01%
10.33%
427.34%
5 Years
774.36%
18.17%
792.53%

Latest dividend: 16 per share ex-dividend date: Jun-28-2024

Risk Adjusted Returns v/s Sensex stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
12.37%
EBIT Growth (5y)
29.40%
EBIT to Interest (avg)
89.78
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
1.76
Tax Ratio
31.62%
Dividend Payout Ratio
30.18%
Pledged Shares
0
Institutional Holding
7.36%
ROCE (avg)
35.38%
ROE (avg)
21.33%
Valuation key factors
Factor
Value
P/E Ratio
38
Industry P/E
33
Price to Book Value
8.63
EV to EBIT
23.43
EV to EBITDA
20.32
EV to Capital Employed
12.42
EV to Sales
4.94
PEG Ratio
16.32
Dividend Yield
0.81%
ROCE (Latest)
49.08%
ROE (Latest)
22.86%
Tecnicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 5 Schemes (3.47%)

FIIs

Held by 47 FIIs (1.3%)

Promoter with highest holding

Nucleus Life Trust (mr. Harsh Vardhan Goenka Is A Trustee) (53.94%)

Highest Public shareholder

Authum Investment And Infrastructure Limited (2.02%)

Individual Investors Holdings

15.58%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Dec'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2024 is 0.29% vs 4.10% in Sep 2024",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2024 is 731.67% vs -84.30% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "172.71",
          "val2": "172.21",
          "chgp": "0.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "49.16",
          "val2": "45.93",
          "chgp": "7.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.12",
          "val2": "0.17",
          "chgp": "-29.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-27.30",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "34.93",
          "val2": "4.20",
          "chgp": "731.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "28.46%",
          "val2": "26.67%",
          "chgp": "1.79%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2024 is 12.04% vs 14.27% in Sep 2023",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2024 is -35.45% vs 25.62% in Sep 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "337.63",
          "val2": "301.36",
          "chgp": "12.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "85.00",
          "val2": "69.53",
          "chgp": "22.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.32",
          "val2": "0.17",
          "chgp": "88.24%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-27.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "30.96",
          "val2": "47.96",
          "chgp": "-35.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "25.18%",
          "val2": "23.07%",
          "chgp": "2.11%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is 12.15% vs 15.40% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is -11.46% vs 29.90% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "510.34",
          "val2": "455.06",
          "chgp": "12.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "134.16",
          "val2": "107.43",
          "chgp": "24.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.44",
          "val2": "0.31",
          "chgp": "41.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-27.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "65.89",
          "val2": "74.42",
          "chgp": "-11.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "26.29%",
          "val2": "23.61%",
          "chgp": "2.68%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2024 is 13.50% vs 16.51% in Mar 2023",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2024 is 29.60% vs 31.39% in Mar 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'24",
        "Mar'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "582.05",
          "val2": "512.81",
          "chgp": "13.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "128.15",
          "val2": "102.69",
          "chgp": "24.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.45",
          "val2": "0.31",
          "chgp": "45.16%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "87.66",
          "val2": "67.64",
          "chgp": "29.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "22.02%",
          "val2": "20.02%",
          "chgp": "2.00%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Standalone) - Dec'24 - QoQstock-summary
Dec'24
Sep'24
Change(%)
Net Sales
172.71
172.21
0.29%
Operating Profit (PBDIT) excl Other Income
49.16
45.93
7.03%
Interest
0.12
0.17
-29.41%
Exceptional Items
0.00
-27.30
100.00%
Standalone Net Profit
34.93
4.20
731.67%
Operating Profit Margin (Excl OI)
28.46%
26.67%
1.79%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2024 is 0.29% vs 4.10% in Sep 2024

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Dec 2024 is 731.67% vs -84.30% in Sep 2024

All Quarterly Resultsstock-summary
Half Yearly Results Snapshot (Standalone) - Sep'24stock-summary
Sep'24
Sep'23
Change(%)
Net Sales
337.63
301.36
12.04%
Operating Profit (PBDIT) excl Other Income
85.00
69.53
22.25%
Interest
0.32
0.17
88.24%
Exceptional Items
-27.30
0.00
Standalone Net Profit
30.96
47.96
-35.45%
Operating Profit Margin (Excl OI)
25.18%
23.07%
2.11%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

Growth in half year ended Sep 2024 is 12.04% vs 14.27% in Sep 2023

Direction Arrows
Standalone Net Profit

Growth in half year ended Sep 2024 is -35.45% vs 25.62% in Sep 2023

All Half Yearly Resultsstock-summary
Nine Monthly Results Snapshot (Standalone) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
510.34
455.06
12.15%
Operating Profit (PBDIT) excl Other Income
134.16
107.43
24.88%
Interest
0.44
0.31
41.94%
Exceptional Items
-27.30
0.00
Standalone Net Profit
65.89
74.42
-11.46%
Operating Profit Margin (Excl OI)
26.29%
23.61%
2.68%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2024 is 12.15% vs 15.40% in Dec 2023

Direction Arrows
Standalone Net Profit

YoY Growth in nine months ended Dec 2024 is -11.46% vs 29.90% in Dec 2023

All Nine Monthly Resultsstock-summary
Annual Results Snapshot (Standalone) - Mar'24stock-summary
Mar'24
Mar'23
Change(%)
Net Sales
582.05
512.81
13.50%
Operating Profit (PBDIT) excl Other Income
128.15
102.69
24.79%
Interest
0.45
0.31
45.16%
Exceptional Items
0.00
0.00
Standalone Net Profit
87.66
67.64
29.60%
Operating Profit Margin (Excl OI)
22.02%
20.02%
2.00%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2024 is 13.50% vs 16.51% in Mar 2023

Direction Arrows
Standalone Net Profit

YoY Growth in year ended Mar 2024 is 29.60% vs 31.39% in Mar 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About RPG Life Sciences Ltd stock-summary
stock-summary
RPG Life Sciences Ltd
Small Cap
Pharmaceuticals & Drugs
RPG Life Sciences Limited, formerly Searle India Limited, started in 1968 as a joint venture with GD Searle, USA. In 1993, GD Searle withdrew from India and sold its holdings to RPG Group. The Company is engaged in manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). RPG Life Sciences Limited was incorporated on March 29, 2007 with the name 'RPG Pharmaceuticals Limited' .
Company Coordinates stock-summary
Company Details
RPG House, 463 Dr Annie Besant Road Worli Mumbai Maharashtra : 400030
stock-summary
Tel: 91-022-24981650
stock-summary
http://www.rpglifesciences.com
stock-summary
info@rpglifesciences.com
Registrar Details
Link Intime India Pvt Ltd, C-13 Pannalal Silk Compound, L B S Marg, Bhandup , Mumbai
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."